Trust the
documentation.
The question isn't whether a supplier has marketing polish. It's whether they can prove identity, purity, sterility, and handling discipline with real documentation.
Three passes before the product page.
Identity, purity, handling. If a supplier can't pass these, the rest doesn't matter.
Identity
Mass spec should confirm that the molecule in the vial is the molecule on the label.
Purity
HPLC results should show usable purity, not just marketing language.
Handling
Endotoxin testing, packaging, and cold-chain discipline determine whether a clean synthesis survives delivery.
Where quality usually breaks.
Most failures don't happen at the headline level. They happen in the handoffs between synthesis, testing, packaging, and retail distribution.
- 01
Raw inputs
Starting materials set the ceiling for purity and sequence fidelity.
- 02
Synthesis lab
Each coupling step creates opportunities for sequence errors and reagent contamination.
- 03
Purification
HPLC is where failed sequences and residuals are separated from the target peptide.
- 04
Testing
Identity, purity, endotoxin, and counterion reporting determine whether the batch is meaningfully characterized.
- 05
Packaging
Lyophilization, vial sealing, and shipping conditions determine whether a good batch stays good.
What a defensible certificate includes.
A COA is the supplier's strongest quality document. If it's weak, treat every other claim as weaker.
Storage conditions, heat exposure, reconstituted concentration, and chain of custody between the tested lot and the shipped vial — none of these are confirmed by a COA alone.
Trifluoroacetate is often introduced during synthesis and can materially reduce active peptide content. Strong suppliers remove it or disclose its content explicitly.
Red flags vs. good signals.
Read this as a decision aid, not a reference document.
- ↳ No COA available or only generic typical values
- ↳ Mass spec missing, so identity is not confirmed
- ↳ HPLC purity below 97%
- ↳ No endotoxin testing listed for injectables
- ↳ Third-party lab not named or not independently verifiable
- ↳ No physical address or contact information
- ↳ Claims of pharmaceutical grade without GMP support
- ↳ Independent third-party COA with a verifiable lab
- ↳ Mass spec plus HPLC in every COA
- ↳ LAL endotoxin assay included for injectables
- ↳ TFA removal or content documented
- ↳ Insulated cold-pack shipping
- ↳ Lot-specific COAs rather than generic product sheets
- ↳ Published testing methodology or quality controls
Most research peptides are sold under a research-use-only designation. That does not make them equivalent to approved medicines.
Several popular peptides were removed from 503A pharmacy compounding. Any clinic marketing them as compounded injectables should be scrutinized carefully.
Sourcing quality, administration technique, and medical supervision remain the user's responsibility when dealing with research compounds.